Spiriva Safe, says the FDA

The mainstay of COPD management is bronchodilatation – the local, and national guidelines rely on beta-2 agonists, and anti-cholinergics.  Recent(ish) data from the TORCH study suggested that inhaled corticosteroids increase the risk of fatal and non-fatal pneumonias.  Unopposed long acting beta agonists have been linked with increased cardiovascular death in asthmatics, although not in COPD.  The most recent ‘scare’ has been whether Spiriva increases cardiovascular death in COPD patients.  Today the FDA rule that there is no compelling evidence to that effect.

Advertisements
Explore posts in the same categories: General Respiratory

Tags: , ,

You can comment below, or link to this permanent URL from your own site.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: